Sitagliptin Treatment in Diabetic COVID-19 Positive Patients

CompletedOBSERVATIONAL
Enrollment

338

Participants

Timeline

Start Date

May 14, 2020

Primary Completion Date

June 15, 2020

Study Completion Date

June 15, 2020

Conditions
Covid19
Interventions
DRUG

Retrospective case-control analysis

Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study

Trial Locations (6)

20089

Humanitas Hospital, Milan

20100

University of Pavia, Pavia

20157

ASST FBF-Sacco P.O. Sacco, Milan

24127

Papa Giovanni XXIII Hospital, Bergamo

27100

IRCCS Policlinico S. Matteo, Pavia

30174

Ospedale dell'Angelo, Venezia-Mestre, Mestre

All Listed Sponsors
collaborator

Papa Giovanni XXIII Hospital

OTHER

collaborator

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER

collaborator

Humanitas Hospital, Italy

OTHER

collaborator

Ospedale dell'Angelo, Venezia-Mestre

OTHER

collaborator

University of Pavia

OTHER

lead

University of Milan

OTHER

NCT04382794 - Sitagliptin Treatment in Diabetic COVID-19 Positive Patients | Biotech Hunter | Biotech Hunter